ABSTRACT
BACKGROUND: Adenylyl cyclase 5 (ADCY5) mutations is associated with heterogenous syndromes: familial dyskinesia and facial myokymia; paroxysmal chorea and dystonia; autosomal-dominant chorea and dystonia; and benign hereditary chorea. We provide detailed clinical data on 7 patients from six new kindreds with mutations in the ADCY5 gene, in order to expand and define the phenotypic spectrum of ADCY5 mutations. METHODS: In 5 of the 7 patients, followed over a period of 9 to 32 years, ADCY5 was sequenced by Sanger sequencing. The other 2 unrelated patients participated in studies for undiagnosed pediatric hyperkinetic movement disorders and underwent whole-exome sequencing. RESULTS: Five patients had the previously reported p.R418W ADCY5 mutation; we also identified two novel mutations at p.R418G and p.R418Q. All patients presented with motor milestone delay, infantile-onset action-induced generalized choreoathetosis, dystonia, or myoclonus, with episodic exacerbations during drowsiness being a characteristic feature. Axial hypotonia, impaired upward saccades, and intellectual disability were variable features. The p.R418G and p.R418Q mutation patients had a milder phenotype. Six of seven patients had mild functional gain with clonazepam or clobazam. One patient had bilateral globus pallidal DBS at the age of 33 with marked reduction in dyskinesia, which resulted in mild functional improvement. CONCLUSION: We further delineate the clinical features of ADCY5 gene mutations and illustrate its wide phenotypic expression. We describe mild improvement after treatment with clonazepam, clobazam, and bilateral pallidal DBS. ADCY5-associated dyskinesia may be under-recognized, and its diagnosis has important prognostic, genetic, and therapeutic implications. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Subject(s)
Adenylyl Cyclases/genetics , Movement Disorders/genetics , Movement Disorders/physiopathology , Aftercare , Child, Preschool , Female , Humans , Infant , Male , PedigreeABSTRACT
Relatively little attention has been paid to integrating gaseous N(2)O generated by wastewater treatment into overall reactive nitrogen (Nr) pollution reduction. We propose that there is potential for substantial reductions in N(2)O emissions through the addition of denitrification processes to existing nitrifying wastewater treatment plants (WWTPs), which are designed to lower ammonia levels but currently do not reduce overall Nr. In addition to providing the benefit of reducing total nitrogen concentrations in the effluent, this kind of WWTP upgrade has been demonstrated to reduce energy consumption and fossil CO(2) emissions. We show that the creation of a greenhouse gas (GHG) crediting system for the wastewater sector could provide a potentially sizable economic incentive on the order of $10 million to $600 million per year in the U.S. for upgrading of nitrifying WWTPs that results in N(2)O reductions, with an ancillary benefit of another $30-100 million per year from electricity savings. Even if biological nitrogen removal (BNR) treatment were mandated by existing and future water quality regulations, a GHG crediting system could still be created to promote BNR design and operation that drive N(2)O emissions below a baseline to even lower levels. In this case GHG credits could offset around 0.5-70% of the operating and maintenance cost for the BNR.
Subject(s)
Nitrogen/isolation & purification , Waste Disposal, Fluid , Waste Management/methods , Water Pollutants, Chemical/isolation & purification , Biodegradation, Environmental , Conservation of Energy Resources , Greenhouse Effect , Models, Chemical , Nitrous Oxide/analysis , United States , Water PurificationABSTRACT
Compounds in the lavendustin A series have been shown to inhibit both protein-tyrosine kinases (PTKs) and tubulin polymerization. Since certain lavendustin A derivatives can exist in conformations that resemble both the trans-stilbene structure of the PTK inhibitor piceatannol and the cis-stilbene structure of the tubulin polymerization inhibitor combretastatin A-4, the possibility exists that the ratio of the two types of activities of the lavendustins could be influenced through the synthesis of conformationally restricted analogues. Accordingly, the benzylaniline structure of a series of pharmacologically active lavendustin A fragments was replaced by either their cis- or their trans-stilbene relatives, and effects on both inhibition of tubulin polymerization and cytotoxicity in cancer cell cultures were monitored. Both dihydrostilbene and 1,2-diphenylalkyne congeners were also prepared and evaluated biologically. Surprisingly, conformational restriction of the bridge between the two aromatic rings of the lavendustins had no significant effect on biological activity. On the other hand, conversion of the three phenolic hydroxyl groups of the lavendustin A derivatives to their corresponding methyl ethers consistently abolished their ability to inhibit tubulin polymerization and usually decreased cytotoxicity in cancer cell cultures as well, indicating the importance of at least one of the phenolic hydroxyl groups. Further investigation suggested that the phenolic hydroxyl group in the salicylamide ring was required for activity, while the two phenol moieties in the hydroquinone ring could be methylated with retention of activity. Two of the lavendustin A derivatives displayed IC(50) values of 1.4 microM for inhibition of tubulin polymerization, which ranks them among the most potent of the known tubulin polymerization inhibitors.
Subject(s)
Antineoplastic Agents/chemical synthesis , Phenols/chemistry , Salicylamides/chemical synthesis , Stilbenes/chemical synthesis , Tubulin/chemistry , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Biopolymers , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Humans , Molecular Conformation , Salicylamides/chemistry , Salicylamides/pharmacology , Stilbenes/chemistry , Stilbenes/pharmacology , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
A series of conformationally restricted analogues were synthesized in order to elucidate the possible effects of different amide conformations of lavendustin A derivatives on cytotoxicity in cancer cell cultures and on inhibition of tubulin polymerization. The conformationally restricted analogues were based on the oxazinedione and isoindolone ring systems. In addition, the amide bond was replaced by both cis and trans alkene moieties. Surprisingly, the results indicated very little effect of conformational restriction on biological activity. Because all of the compounds synthesized had similar cytotoxicities and potencies as tubulin polymerization inhibitors, the side chain present on the aniline ring system does not appear to be important in the biological effects of the lavendustins. The hydroquinone ring of lavendustin A may be a more important determinant of the biological activity than the structure surrounding the aniline ring.
Subject(s)
Antineoplastic Agents/chemical synthesis , Phenols/chemical synthesis , Tubulin/chemistry , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Biopolymers , Drug Screening Assays, Antitumor , Humans , Molecular Conformation , Phenols/chemistry , Phenols/pharmacology , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Laulimalide is a cytotoxic natural product that stabilizes microtubules. The compound enhances tubulin assembly, and laulimalide is quantitatively comparable to paclitaxel in its effects on the reaction. Laulimalide is also active in P-glycoprotein overexpressing cells, while isolaulimalide, a congener without the drug's epoxide moiety, was reported to have negligible cytotoxic and biochemical activity [Mooberry et al. (1999) Cancer Res. 59, 653-660]. We report here that laulimalide binds at a site on tubulin polymer that is distinct from the taxoid site. We found that laulimalide, while as active as paclitaxel, epothilone A, and eleutherobin in promoting the assembly of cold-stable microtubules, was unable to inhibit the binding of radiolabeled paclitaxel or of 7-O-[N-(2,7-difluoro-4'-fluoresceincarbonyl)-L-alanyl]paclitaxel, a fluorescent paclitaxel derivative, to tubulin. Confirming this observation, we demonstrated that microtubules formed in the presence of both laulimalide and paclitaxel contained near-molar quantities, relative to tubulin, of both drugs. Laulimalide was active against cell lines resistant to paclitaxel or epothilones A and B on the basis of mutations in the M40 human beta-tubulin gene. We also report that a laulimalide analogue lacking the epoxide moiety, while less active than laulimalide in biochemical and cellular systems, is probably more active than isolaulimalide. Further exploration of the role of the epoxide in the interaction of laulimalide with tubulin is therefore justified.